He is the former Head of Risk Management Section at the European Medicines Agency, and the former Head of Pharmacovigilance, Strategy and Development at the State Institute for Drug Control in the Czech Republic.
He has unique education in Quality and Safety in Healthcare (MSc) from the Imperial College London, and trained as a physician at Charles University in Prague (MD). He has written and/or contributed to many national and international guidelines, including ICH E2F, EMA Guideline on Safety and Efficacy Follow-up – Risk Management of Advanced Therapies, and parts of Volume 9A.
Jan joined the PrimeVigilance Board of Directors in November 2016 and has led the organisation as CEO since April 2017.
+44 (0)1483 307920
(+1) 781 703 5540
United Kingdom (Head Office)